Nanosonics Limited · ASX:NAN
Nanosonics — Shareholder Meeting (November 2025)
33 slides from Nanosonics's shareholder meeting presentation, Nov 5, 2025
Slide 1: Welcome to Nanosonics' Annual General Meeting
For personal use only DRAFT – v4 WELCOME TO NANOSONICS’ ANNUAL GENERAL MEETING 5 NOVEMBER 2025
Slide 2: Your Board
Your Board Diverse skillset and strong independence For personal use only Steven Sargent Michael Kavanagh Marie McDonald BSc Lisa McIntyre BSc Tracey Batten MBBS, Larry Marshall BSc Gerard Dalbosco BBus, FAICD, FTSE BSc, MBA (Advanced) (Hons), LLB (Hons) (Hons), PhD MBA (Harvard), FAICD, (Hons), PhD
Slide 3: How to ask a question
How to ask a question For personal use only 1. To ask a written question select the Q&A icon. 2. Select the topic your question relates to from the drop-down list. 3. Type your question in the text box and press the send button. 4. To ask a verbal question follow the instructions below the broadcast
Slide 4: How to vote
How to vote For personal use only 1. When the poll is open, select the vote icon at the top of the screen. 2. To vote, select either For, Against or Abstain. 3. You will see a vote confirmation. 4. To change or cancel your vote “click here to change your vote” at any time until the poll is closed. N
Slide 5: Chairman's Address
For personal use only Chairman’s Address
Slide 6: Nanosonics pioneers groundbreaking technologies to prevent infections
28 million patients protected every year For personal use only TROPHON CORIS Nanosonics 37,000 devices1 Phased pioneers ground- commercialisation breaking technologies to prevent life- altering infections. Nanosonics Limited | AGM 2025 | 6 1. Cumulative global sales of new installed base units.
Slide 7: Evolving healthcare landscape
Evolving healthcare landscape Nanosonics is well positioned to execute on the opportunity For personal use only Growth in Ultrasound Healthcare acquired Automation Digitisation & Changing Operating & Endoscopy infections (HAIs) Traceability Environment Technology advancements The negative impacts on
Slide 8: Driving value creation
Driving value creation For personal use only Trusted brand in automated high level disinfection with 1 over 37,000 unit installed base Customer value expansion powering high margin recurring revenue. Disciplined capital allocation driving operating leverage and EBIT growth today. Strong cash generat
Slide 9: Launching up to $20m share buy-back
Launching up to $20m share buy-back Strong financial position On-market buy back For personal use only FY25 REVENUE • On-market share buy-back of up to $20 million in FY26 $198.6M 17% YoY • Disciplined capital allocation means Nanosonics retains capacity to invest in the next growth 14% CC1 horizon,
Slide 10: Sustainability
Sustainability For personal use only Significant FY25 renewable Key FY26 sustainability targets energy achievement Nanosonics converted to a 100% renewable energy source for Caring for our Caring for our Caring for our Caring for our Australian and US customers & partners planet people business oper
Slide 11: Board of Directors
Board of Directors For personal use only Steven Sargent BBus, FAICD, FTSE Michael Kavanagh BSc, MBA Marie McDonald BSc (Hons), Lisa McIntyre BSc (Hons), PhD Non-executive Director and Chairman (Advanced) LLB (Hons) Non-executive Director CEO, President and Managing Director Non-executive Director Tr
Slide 12: CEO Address
For personal use only CEO Address
Slide 13: Nanosonics' mission
Nanosonic’s mission For personal use only WHY HOW WHAT To improve the By transforming By introducing safety of the way innovative patients, infection technologies clinics, their prevention that deliver staff and the practices are improved environment. understood and standards of conducted. care. Nan
Slide 14: FY25 financial highlights
FY25 financial highlights Strong revenue and profit growth demonstrating strength of recurring revenue business model For personal use only TOTAL REVENUE RECURRING REVENUE CAPITAL REVENUE (CONSUMABLES & SERVICE) $198.6M $146.1M $52.5M 17% YoY 20% YoY 9% YoY 14% CC1 CONSOLIDATED PROFIT BEFORE TAX CAS
Slide 15: Financial strength from disciplined capital management
Financial strength from disciplined capital management For personal use only Growing cash position Disciplined capital allocation Global Installed Base Cash Balance $m 40000 180 35000 160 CORIS trophon 140 30000 INSTALLED BASE (DEVICES)1 CASH BALANCE $M GLOBAL CUMULATIVE 120 25000 100 Product Intern
Slide 16: Operational milestones in FY25
Operational milestones in FY25 Strong foundations to achieve the next growth horizon Innovation For personal use only CORIS® FDA De Novo trophon3® and trophon2® 7 new patent families clearance Plus development Operations Consumables Service infrastructure CORIS supply chain manufacturing facility ex
Slide 17: Nanosonics growth strategy
Nanosonics growth strategy Transforming medical device reprocessing for improved patient safety VALUE CREATION For personal use only By establishing new standards of care in reusable medical device reprocessing and Expanding into new Medical Device Leading ultrasound reprocessing Transforming endosc
Slide 18: Key trophon growth drivers
Key trophon growth drivers Capital Capital software upgrades For personal use only trophon3 - ongoing new Trophon2 Plus - Accelerate upgrade adoption installed base growth software upgrade – approximately 10,000 EPR internationally through deeper package opportunity, for device opportunity for penet
Slide 19: CORIS milestones to commercialisation
CORIS milestones to commercialisation1 FY25 & FY26 milestones Device manufacturing USA Consumables Peer review Publication and Regional Clinical Simulation / FDA De Novo & supply chain manufacturing Podium Presentations on Customer education labs clearance established site registered established sup
Slide 20: Significant growth opportunity: CORIS business model & revenue streams
Significant growth opportunity CORIS business model & revenue streams For personal use only Number of daily cycles per machine expected to be a Capital equipment to be multiple of trophon cycles at installed in endoscope a higher price to trophon reprocessing centres. cycle. Note, current cost of Ca
Slide 21: Summary
Summary For personal use only FY26 Beyond Sales and installations have commenced for Continued customer value expansion trophon3 and trophon2 Plus, supporting market leadership. Service expansion CORIS controlled market release on track to trophon3 - ongoing market penetration commence in FY26, with
Slide 22: Resolutions
For personal use only Resolutions
Slide 23: Re-election of a Director, Mr Steven Sargent
Resolution 1 Re-election of a Director, Mr Steven Sargent For personal use only To consider and, if thought Proxy votes received Number % fit, to pass the following resolution as an ordinary For: 218,471,527 98.69 resolution: That Mr. Steven Sargent, Against: 2,678,954 1.21 Steven Sargent being elig
Slide 24: Election of a Director, Mr Gerard Dalbosco
Resolution 2 Election of a Director, Mr Gerard Dalbosco For personal use only To consider and, if thought fit, Proxy votes received Number % to pass the following resolution as an ordinary For: 209,778,780 94.77 resolution: That Mr Gerard Dalbosco, Against: 11,364,961 5.13 Gerard Dalbosco who was ap
Slide 25: Adoption of Remuneration Report
Resolution 3 Adoption of Remuneration Report For personal use only To consider and, if thought fit, to pass the following Proxy votes received Number % advisory, non-binding resolution (in accordance with section 250R(3) of the Corporations Act) as an For: 218,161,870 99.21 ordinary resolution: That
Slide 26: Issue of 59,233 Service Rights to CEO Michael Kavanagh
Resolution 4 Issue of 59,233 Service Rights to the Chief Executive Officer and President, Mr Michael Kavanagh, in respect of Mr Kavanagh’s 2025 Short Term Incentive grant (FY25 STI) and under the Nanosonics Equity Plan For personal use only To consider and, if thought fit, to pass the following reso
Slide 27: Issue of 405,184 Performance Rights to CEO Michael Kavanagh
Resolution 5 Issue of 405,184 Performance Rights to the Chief Executive Officer and President, Mr Michael Kavanagh, in respect of Mr Kavanagh’s 2025 Long-Term Incentive grant (FY26 LTI) and under the Nanosonics Equity Plan For personal use only To consider and, if thought fit, to pass the following
Slide 28: Approval of the Nanosonics Global Employee Share Plan
Resolution 6 Approval of the Nanosonics Global Employee Share Plan For personal use only To consider and, if thought fit, to pass the following Proxy votes received Number % resolution as an ordinary resolution: For: 220,690,643 99.74 That, for the purpose of ASX Listing Rule 7.2 (Exception 13) and
Slide 29: How to ask a question
How to ask a question For personal use only 1. To ask a written question select the Q&A icon. 2. Select the topic your question relates to from the drop-down list. 3. Type your question in the text box and press the send button. 4. To ask a verbal question follow the instructions below the broadcast
Slide 30: How to vote
How to vote For personal use only 1. When the poll is open, select the vote icon at the top of the screen. 2. To vote, select either For, Against or Abstain. 3. You will see a vote confirmation. 4. To change or cancel your vote “click here to change your vote” at any time until the poll is closed. N
Slide 31: How to ask a question
How to ask a question For personal use only 1. To ask a written question select the Q&A icon. 2. Select the topic your question relates to from the drop-down list. 3. Type your question in the text box and press the send button. 4. To ask a verbal question follow the instructions below the broadcast
Slide 32: Disclaimer
Disclaimer This presentation is intended to provide a general outline only and is not intended to be No representation, warranty or assurance (express or implied) is given or made in a definitive statement on the subject matter covered in it. The information in this relation to any forward looking s
Slide 33: Thank you
For personal use only Thank you